BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 18941118)

  • 1. miR-34a as part of the resistance network in chronic lymphocytic leukemia.
    Zenz T; Mohr J; Eldering E; Kater AP; Bühler A; Kienle D; Winkler D; Dürig J; van Oers MH; Mertens D; Döhner H; Stilgenbauer S
    Blood; 2009 Apr; 113(16):3801-8. PubMed ID: 18941118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.
    Fabbri M; Bottoni A; Shimizu M; Spizzo R; Nicoloso MS; Rossi S; Barbarotto E; Cimmino A; Adair B; Wojcik SE; Valeri N; Calore F; Sampath D; Fanini F; Vannini I; Musuraca G; Dell'Aquila M; Alder H; Davuluri RV; Rassenti LZ; Negrini M; Nakamura T; Amadori D; Kay NE; Rai KR; Keating MJ; Kipps TJ; Calin GA; Croce CM
    JAMA; 2011 Jan; 305(1):59-67. PubMed ID: 21205967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
    Kojima K; Duvvuri S; Ruvolo V; Samaniego F; Younes A; Andreeff M
    Cancer; 2012 Feb; 118(4):1023-31. PubMed ID: 21761401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
    Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
    Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
    Visone R; Rassenti LZ; Veronese A; Taccioli C; Costinean S; Aguda BD; Volinia S; Ferracin M; Palatini J; Balatti V; Alder H; Negrini M; Kipps TJ; Croce CM
    Blood; 2009 Oct; 114(18):3872-9. PubMed ID: 19717645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
    Zhu HJ; Liu L; Fan L; Zhang LN; Fang C; Zou ZJ; Li JY; Xu W
    Leuk Lymphoma; 2013 Dec; 54(12):2712-9. PubMed ID: 23517560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
    Zenz T; Mohr J; Edelmann J; Sarno A; Hoth P; Heuberger M; Helfrich H; Mertens D; Dohner H; Stilgenbauer S
    Leuk Lymphoma; 2009 Mar; 50(3):510-3. PubMed ID: 19347737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis.
    Turgut B; Vural O; Pala FS; Pamuk GE; Tabakcioğlu K; Demir M; Ongören S; Soysal T; Algüneş C
    Leuk Lymphoma; 2007 Feb; 48(2):311-20. PubMed ID: 17325891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.
    Blume CJ; Hotz-Wagenblatt A; Hüllein J; Sellner L; Jethwa A; Stolz T; Slabicki M; Lee K; Sharathchandra A; Benner A; Dietrich S; Oakes CC; Dreger P; te Raa D; Kater AP; Jauch A; Merkel O; Oren M; Hielscher T; Zenz T
    Leukemia; 2015 Oct; 29(10):2015-23. PubMed ID: 25971364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia.
    Wang LQ; Kwong YL; Wong KF; Kho CS; Jin DY; Tse E; Rosèn A; Chim CS
    J Transl Med; 2014 Feb; 12():52. PubMed ID: 24559316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation.
    Dijkstra MK; van Lom K; Tielemans D; Elstrodt F; Langerak AW; van 't Veer MB; Jongen-Lavrencic M
    Leukemia; 2009 Mar; 23(3):625-7. PubMed ID: 18818704
    [No Abstract]   [Full Text] [Related]  

  • 13. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
    Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
    Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.
    Boysen J; Sinha S; Price-Troska T; Warner SL; Bearss DJ; Viswanatha D; Shanafelt TD; Kay NE; Ghosh AK
    Leukemia; 2014 Feb; 28(2):451-5. PubMed ID: 24217154
    [No Abstract]   [Full Text] [Related]  

  • 15. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.
    Sampath D; Calin GA; Puduvalli VK; Gopisetty G; Taccioli C; Liu CG; Ewald B; Liu C; Keating MJ; Plunkett W
    Blood; 2009 Apr; 113(16):3744-53. PubMed ID: 19096009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia.
    Abo Elwafa R; Abd Elrahman A; Ghallab O
    Clin Transl Oncol; 2021 Jan; 23(1):92-99. PubMed ID: 32468342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
    Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
    Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
    Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR
    Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.
    Merkel O; Asslaber D; Piñón JD; Egle A; Greil R
    Cell Cycle; 2010 Jul; 9(14):2764-8. PubMed ID: 20581456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
    Bacalini MG; Tavolaro S; Peragine N; Marinelli M; Santangelo S; Del Giudice I; Mauro FR; Di Maio V; Ricciardi MR; Caiafa P; Chiaretti S; Foà R; Guarini A; Reale A
    Exp Hematol; 2012 Mar; 40(3):197-206.e1. PubMed ID: 22120020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.